Vernalis, Daiichi form oncology drug discovery collaboration

Vernalis' platform is designed to identify molecules with low molecular weights that interact with the binding site of the target.

Daiichi Sankyo has tapped Vernalis for its drug discovery expertise. The agreement will see Vernalis turn its fragment and structure-based drug discovery platform on undisclosed cancer targets.

Japan’s Daiichi is making undisclosed financial commitments to access the platform. Previous deals suggest the sum will be fairly small, at least in the near term. Servier paid €2 million ($2.4 million) upfront and committed more in fees, milestones and other payments to strike a one-target cancer agreement based on the same drug discovery platform in March.

The platform is designed to identify molecules with low molecular weights that interact with the binding site of the target. Identification of these fragments gives researchers a starting point for their efforts to develop ligands and drugs. 


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Vernalis is using the platform in active drug discovery collaborations with companies including Servier and Lundbeck. And it has a history of working with other well-known drug developers such as Genentech and Novartis. 

Management celebrated adding Daiichi to the list.

“This is another excellent endorsement of our market leading fragment and structure-based drug discovery platform and we look forward to a successful collaboration with Daiichi Sankyo,” Vernalis CEO Ian Garland said in a statement. 

The new deals with Daiichi and Servier—plus milestones from other agreements with the French drugmaker—have been bright spots for Vernalis in a tricky year, although they have failed to fully lift the gloom.     

Vernalis’ woes stem from the back-to-back FDA rejections it received in April and August. Those setbacks quashed Vernalis’ hopes of getting CCP-07 and CCP-08 to market in time for this winter’s cough-cold season in the U.S. 

The challenge now is to work through the problems—which have a common cause—that led to the complete response letters in time to get the drugs approved ahead of the 2018-19 cough-cold season.   

Suggested Articles

The FDA warned healthcare providers about cybersecurity vulnerabilities within certain clinical information systems made by GE Healthcare.

Weeks after receiving FDA approval for its in-office eardrum tube device, Tusker Medical has been picked up by Smith & Nephew for an undisclosed sum.

What a difference a day makes in biotech.